GDTC
CytoMed Therapeutics Ltd
$1.14
-1.18%
$13.6M
No data for this timeframe.
Vol
Market Cap$13.6M
Cap SizeNano Cap
SEC Reports4
Recent Activity
May 15, 2026
SEC
Chairman and Director Choo Chee Kong acquired 112,000 ordinary shares in a private purchase on May 13, 2026, and stated
6-K — Impact 5/10
May 11, 2026
SEC
CytoMed Therapeutics announced the name change of its wholly owned subsidiary from Advance Cancer Centre Pte. Ltd. to Cy
6-K — Impact 3/10
May 4, 2026
earnings_calendar
GDTC Q4 2025 Earnings Scheduled — 2026-05-04
Mar 31, 2026
SEC
CytoMed Therapeutics reported full-year 2025 financial results with revenue growth to $780,857 but a wider net loss of $
6-K — Impact 6/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 10, 2024 | Benchmark | REITERATE | Speculative Buy → Speculative Buy |
| Jun 11, 2024 | Benchmark | REITERATE | Speculative Buy → Speculative Buy |
| Dec 4, 2023 | Benchmark | REITERATE | Speculative Buy → Speculative Buy |
| Jul 21, 2023 | Benchmark | INITIATE | Speculative Buy |
Latest Reports
BULLISH
6-K
5/10
Chairman and Director Choo Chee Kong acquired 112,000 ordinary shares in a private purchase on May 13, 2026, and stated
May 15, 2026
NEUTRAL
6-K
3/10
CytoMed Therapeutics announced the name change of its wholly owned subsidiary from Advance Cancer Centre Pte. Ltd. to Cy
May 11, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 4.8/10.
BULLISH
6-K
5/10
Chairman and Director Choo Chee Kong acquired 112,000 ordinary shares in a private purchase on May 1
May 15, 2026
NEUTRAL
6-K
3/10
CytoMed Therapeutics announced the name change of its wholly owned subsidiary from Advance Cancer Ce
May 11, 2026
MIXED
6-K
6/10
CytoMed Therapeutics reported full-year 2025 financial results with revenue growth to $780,857 but a
Mar 31, 2026
NEUTRAL
20-F
5/10
CytoMed Therapeutics' 20-F filing confirms ongoing Phase I clinical trials for its lead product cand
Mar 31, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Oct 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2025-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 10, 2024 | Benchmark | REITERATE | Speculative Buy | Speculative Buy |
| Jun 11, 2024 | Benchmark | REITERATE | Speculative Buy | Speculative Buy |
| Dec 4, 2023 | Benchmark | REITERATE | Speculative Buy | Speculative Buy |
| Jul 21, 2023 | Benchmark | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 4, 2026
earnings_calendar
GDTC Q4 2025 Earnings Scheduled — 2026-05-04